CA-MATRIXX-SOFTWARE
MATRIXX Software , a global leader in cloud native, 5G monetization solutions, today announced performance results from its IBM Cloud for Telecommunications implementation. Anticipating the urgent need of Communications Service Providers (CSPs) to monetize their 5G investments, MATRIXX Software’s 5G CCS established a performance milestone of 200K transactions per second (TPS) across 100M subscribers running on IBM Cloud for Telecommunications.
With average end-to-end latency of 7.4 milliseconds across all operations, including network gateways and routing, this performance benchmark demonstrates that MATRIXX on IBM Cloud can enable CSPs to run critical network workloads in the cloud at the same or better performance levels as on-premise. MATRIXX successfully delivered seamless scalability for an efficient, flexible cloud native charging solution, which opens the door for CSPs to experiment with new ways of monetizing 5G workloads.
This is an important milestone as 5G represents a $667B opportunity by 2026 and impacts every industry. To explore and test new revenue streams, CSPs need to accelerate their network transformation to handle increased traffic from new services and devices. With more than 30 billion IoT devices predicted by 2025, telco networks and IT infrastructure will need proven capability to scale both vertically and horizontally if they are to manage the 10-20x growth in traffic anticipated from 5G.
Using a simulated blend of 4G and 5G traffic, MATRIXX used the IBM Cloud for Telecommunications, built on Red Hat OpenShift, to provide more flexibility in harnessing data across cloud and on-premises environments. The performance benchmark demonstrates how together, MATRIXX and IBM Cloud for Telecommunications can deliver consistent throughput and latency, which helps enable providers to run critical network workloads such as charging in the cloud.
“As telcos deploy 5G network infrastructure, they are looking for validation of new revenue models that 5G enables,” said Marc Price, MATRIXX CTO. “We have collaborated with IBM to achieve industry-leading metrics on its IBM Cloud for Telecommunications, showcasing for CSPs how their 5G monetization strategies will be achievable as the number and diversity of connected devices increases exponentially.”
This is the first lab outcome since MATRIXX joined IBM’s partner ecosystem. These results demonstrate the seamless scalability of MATRIXX’s patented converged charging technology when combined with the IBM Cloud for Telecommunications. Working in close collaboration, IBM’s Hybrid Cloud Build Team and MATRIXX have developed a blueprint for best practices and configuration requirements they can deliver to CSP’s to address their unique performance targets.
“As 5G transforms the telco industry, many operators face the challenge of managing growing volumes of data, voice, and multi-media services from millions of end users. The IBM Cloud for Telecommunications is designed to address these specific challenges and transform their networks into flexible platforms that can efficiently scale,” said Steve Goetz, Vice President & Senior Partner of Global Telecommunications, Media & Entertainment Industry at IBM. “As a leading Network and 5G Transformation partner, IBM Global Business Services is proud to support our ecosystem partner MATRIXX to help them achieve such a notable milestone. These results will accelerate business transformation and agility as customers modernize enterprise applications and infrastructure to unlock the power of 5G and edge.”
With innovations in business rule execution, transaction processing, data management and clustering, the cloud native MATRIXX 5G CCS delivers consistent throughput and latency within heterogenous network environments, managing sophisticated price plans, across hundreds of millions of unique subscribers and devices.
MATRIXX is part of IBM's partner ecosystem collaborating on the IBM Cloud for Telecommunications to help network equipment providers, independent software vendors (ISVs), software-as-a-service providers, and hardware partners accelerate business transformation by unlocking the power of 5G and edge. The IBM Cloud for Telecommunications is an open, hybrid cloud architecture that leverages Red Hat OpenShift and IBM Cloud Satellite to enable clients to deploy IBM Cloud services anywhere: on the cloud, on premises or at the edge, while addressing unique industry regulatory and security requirements. The IBM Hybrid Cloud Build Team is an elite team dedicated to help partners maximize the value of open hybrid cloud environments and unlock the power of AI for their business and customers.
To learn more about the collaboration between MATRIXX and IBM, watch this video interview between Marc Price and Omkar Nimbalkar, VP WW Hybrid Cloud Build Team at IBM Hybrid Cloud Ecosystem Group.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS), enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom